DEAR EDITOR, Several papers have reported that tumour necrosis factor-o inhibitors, such
as adalimumab (ADA), induce interstitial pneumonia (IP) in patients with rheumatoid arthritis …

A 19-year-old heterosexual man presented with several well-demarcated, red and scaly
facial skin lesions. Five weeks previously, he had been started on ustekinumab 45 mg to …

DEAR EDITOR, The baseline risk of infection is generally higher in older adults, which has
raised concern for the use of biologic and systemic nonbiologic immunomodulatory …

MADAM, A 47-year-old man with a 32-year history of chronic plaque psoriasis and psoriatic
arthritis, well controlled by infusions of the tumour necrosis factor (TNF) inhibitor infliximab 5 …

Abstract Dear Editor, Psoriasis is an autoimmune T cell-mediated disease with a mean
prevalence in Europe and North America of about 2%. Ustekinumab for the treatment of …

When the efficacy of infliximab in psoriasis was first reported in 2001, 1 no new systemic
treatments had been introduced since ciclosporin in the 1980s, and prolonged inpatient …

Methotrexate has been the primary conventional systemic therapy for psoriasis for 40 years
and as such could be regarded as a gold standard maintenance therapy against which new …

JLE - European Journal of Dermatology - Psoriasis vulgaris in a hepatitis B virus carrier
successfully treated with secukinumab and entecavir combination therapy JLE Home Bookstore …

2 Shapiro J, Cohen AD, Weitzman D et al. Psoriasis and cardiovascular risk factors: a case–
control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol 2012; 66 …

Introduction Biologics are a standard therapy for patients with moderate-to-severe psoriasis,
yet treatment persistence is essential to achieve disease control. Compared with other …